Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Arjun V. Balar

Oncology
320 W 38th St Apt 424, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in WT1-Related Wilms Tumor Syndromes
320 W 38th St Apt 424, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arjun Balar is an Oncologist in New York, New York. Dr. Balar is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Prostate Cancer, Muscle Invasive Bladder Cancer, and Thrombectomy.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

320 W 38th St Apt 424, New York, NY 10018

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder
A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Biological, Radiation, Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Enrollment Status: Terminated
Publish Date: April 25, 2025
Intervention Type: Other, Drug
Study Drug: Afatinib
Study Phase: Phase 2
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Enrollment Status: Terminated
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

71 Total Publications

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.
Journal: Future oncology (London, England)
Published: September 01, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert J. Motzer
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert J. Motzer
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (2.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Motzer is an Oncologist in New York, New York. Dr. Motzer is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Teratoma of the Mediastinum, Nephrectomy, and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Martin H. Voss
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Martin H. Voss
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (2.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Martin Voss is an Oncologist in New York, New York. Dr. Voss is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert S. Alter
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert S. Alter
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (9.5 miles away)
201-996-5900
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Robert Alter is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Alter is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Urothelial Cancer, Endoscopy, and Nephrectomy. Dr. Alter is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Balar's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile